The investment includes $1.5 billion for capital expenditures to enhance and expand U.S. manufacturing facilities, alongside $500 million dedicated to research and development (R&D) to drive high-impact innovation. Marc N. Casper, chairman, president, and chief executive officer of Thermo Fisher Scientific, stated: “Thermo Fisher’s commitment to U.S. manufacturing reflects our confidence that America will continue to lead the world in science and innovation. By expanding our U.S. operations, we ensure that life-saving medicines and therapies will continue to be developed and produced in America for decades to come.”
Thermo Fisher operates 64 manufacturing facilities across 37 states, producing analytical instruments, specialty diagnostics, and life sciences solutions, while also providing contract development and manufacturing services for pharmaceutical companies. Since 2017, the company has grown significantly, doubling its revenue from $21 billion to $43 billion and increasing its U.S. workforce from 28,000 to over 50,000 employees. The company currently invests $1 billion annually in U.S.-based R&D.
The new investment will create high-paying jobs, expand manufacturing and laboratory service capacities, and further innovation in the life sciences. A company spokesperson noted: “These additional investments to our American manufacturing capacity support a resilient U.S. healthcare supply chain and will have a strong multiplier effect across the American economy.” This initiative builds on Thermo Fisher’s established presence in the U.S., reinforcing its role as a key contributor to the nation’s economic and scientific advancement.
By bolstering domestic production and research, Thermo Fisher aims to ensure the availability of critical medicines and therapies while fostering sustainable growth in the U.S. life sciences sector. The investment reflects a long-term commitment to supporting biopharmaceutical innovation and enhancing economic opportunities across the country.
